Surface Oncology Inc

Surface Oncology — Investor Presentation (January 2020)

39 slides from Surface Oncology's investor presentation, Jan 13, 2020

  1. Slide 1: Breaking through for patients with cancer

    Breaking through for patients with cancer January 2020 Exhibit 99.1

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of ope

  3. Slide 3: Break Through: strong foundation and mission

    BREAK THROUGH Financial resources and strategic partners provide STRONG FOUNDATION On a mission to dramatically IMPROVE CURE RATES FOR CANCER Proven leadership and UNIQUELY COLLABORATIVE SCIENTIFIC ADVISORS Deep biological expertise across the TUMOR MICROENVIRONMENT Focus on differentiated targets b

  4. Slide 4: Surface Oncology at a Glance

    SURFACE ONCOLOGY. Surface Oncology at a Glance

  5. Slide 5: Recent Corporate Highlights

    Recent Corporate Highlights Filed INDs for SRF617 (CD39) and SRF388 (IL-27) New clinical candidate announced: SRF813, targeting CD112R Multiple poster presentations at SITC annual meeting Ramy Ibrahim, M.D. (CMO of the Parker Institute) added to the Board Cash at end of Q3 2019: $111.8 million

  6. Slide 6: Broad Approach Targeting the Immunosuppressive Tumor Microenvironment

    Block Suppressive Metabolites and Cytokines Activate Macrophages Deplete Regulatory T Cells Activate Natural Killer Cells Broad Approach Targeting the Immunosuppressive Tumor Microenvironment

  7. Slide 7: Collaboration With Renowned Advisors

    Collaboration With Renowned Advisors Oncology Immunology Translational science Clinical development A break through philosophy Transformative impact for patients Collective learning SCIENTIFIC ADVISORY BOARD SURFACE TEAM Deep expertise in: Commitment to: Sasha Rudensky, PhD Carla Rothlin, PhD John S

  8. Slide 8: Broad Portfolio Targeting the Tumor Microenvironment

    Broad Portfolio Targeting the Tumor Microenvironment

  9. Slide 9: Overview of Ongoing Phase 1 Trial NZV930

    Overview of Ongoing Phase 1 Trial NZV930 Single Agent Dose Escalation NZV930 with PDR001 (Anti-PD-1) NZV930 with NIR178 (A2AR antagonist) NZV930, NIR178 & PDR001 (1) NSCLC, TNBC, Ovarian Cancer, MSS Colorectal, Pancreatic Ductal Adenocarcinoma, Renal Cell Carcinoma Enrollment spanning three combinat

  10. Slide 10: Management Team with Proven Track Record of Success

    Rob Ross, MD Chief Medical Officer Vito Palombella, PhD Chief Scientific Officer Pam Holland, PhD Vice President, Cancer Biology Jeff Goater Chief Executive Officer Jessica Fees Senior Vice President, Finance and Business Operations Bob Steininger Senior Vice President, CMC Liisa Nogelo-Kerr General

  11. Slide 11: Overview of SRF617 Targeting CD39 for Immune System Activation

    Overview of SRF617 Targeting CD39 for Immune System Activation

  12. Slide 12: Targeting CD39 Can Activate Both Innate and Adaptive Immunity

    Targeting CD39 Can Activate Both Innate and Adaptive Immunity ATP AMP Adenosine Cell stress/ damage/ death CD39 CD73 Innate and adaptive immune response (adaptive) (innate) NK cell T cell Myeloid cell Macrophage Dendritic cell

  13. Slide 13: SRF617 Engages the Adaptive Immune System by Reducing Adenosine Levels

    SRF617 Engages the Adaptive Immune System by Reducing Adenosine Levels ATP AMP Adenosine Cell stress/ damage/ death CD39 CD73 Innate and adaptive immune response (adaptive) SRF617 SRF617 Reduces Plasma Adenosine Levels in Tumor-Bearing Mice SRF617

  14. Slide 14: SRF617 Mediated CD39 Blockade is Immunostimulatory

    14 ATP AMP Adenosine Cell stress/ damage/ death CD39 CD73 Innate and adaptive immune response (adaptive) SRF617 SRF617 Mediated CD39 Blockade is Immunostimulatory By Reducing Adenosine Levels, SRF617 Stimulates T Cell Responses

  15. Slide 15: SRF617 Engages the Innate Immune System By Increasing Extracellular ATP

    15 Cell stress/ damage/ death (innate) ATP AMP Adenosine CD39 CD73 Innate and adaptive immune response SRF617 SRF617 Monotherapy or Combination with Gemcitabine Leads to Increased ATP Levels in Human Pancreatic Cancer Cultures * SRF617 Engages the Innate Immune System By Increasing Extracellular ATP

  16. Slide 16: SRF617 Stimulates Key Components of the Innate Immune System

    SRF617 Stimulates Key Components of the Innate Immune System 16 Cell stress/ damage/ death (innate) ATP AMP Adenosine CD39 CD73 Innate and adaptive immune response SRF617 SRF617 Stimulates Dendritic Cells, A Key Component of the Innate Immune System

  17. Slide 17: CD39 Inhibition Demonstrates Potent Anti-tumor Activity

    CD39 Inhibition Demonstrates Potent Anti-tumor Activity 17 SRF617 Single Agent Activity in Xenograft MOLP8 In Vivo Model Murine Anti-CD39 Surrogate Cooperates with Anti-PD1 in CT26 Model, Increasing Cures Days on Study 10/18 CR 4/16 CR (Rechallenge)

  18. Slide 18: Patterns of CD39 TME Expression Lead to Translational Hypotheses

    Patterns of CD39 TME Expression Lead to Translational Hypotheses in Tumor Types with High Clinical Need CD39 TIL expression CD39/CK Gastric CA CD39 CD39 stromal expression Pancreatic CA CD39/CK 18

  19. Slide 19: CD39 Expression Increases After Anti-PD-(L)1 Exposure

    CD39 Expression Increases After Anti-PD-(L)1 Exposure *Surface data 5 individual PBMC donors -/+ Nivolumab at 10ug/ml 96-Hour incubation Cell types and %CD39 expression determined by flow *Clinical data, Corvus, SITC 2017 CD39 expression analysis from RCC and NSCLC screening biopsies Resistant pts t

  20. Slide 20: SRF617 Clinical Development Plan

    SRF617 Clinical Development Plan Phase 1/1b 20 Dose Escalation: Patients with advanced solid tumors Establish safe monotherapy dose (accelerated & 3+3 design) Establish safe combination therapy dose(s); anticipate staggered start after monotherapy Biopsy Expansion Cohort: Evaluate on-target tumor ti

  21. Slide 21: Key Phase 1 Bioassays to Assess Biologic POC

    Key Phase 1 Bioassays to Assess Biologic POC 21 PBMC Target Occupancy CD39 Enzymatic Activity by IHC Allows for Direct Measurement of CD39 Inhibition within the TME Binding of SRF617 to PBMCs is Highly Correlated to Enzymatic Inhibition

  22. Slide 22: SRF617 Antibody Targeting CD39

    High affinity, fully human IgG4 antibody against human CD39 Potent inhibitor of enzymatic activity IND filed in November 2019 Dual mechanism of action: Significant reduction of adenosine and increased levels of ATP leads to increased T cell proliferation and dendritic cell maturation SRF617 Antibody

  23. Slide 23: Overview of SRF388 Targeting IL-27 to Enhance Immune Activity in the TME

    Overview of SRF388 Targeting IL-27 to Enhance Immune Activity in the TME

  24. Slide 24: IL-27 is an Immunosuppressive Cytokine Upregulated During Pregnancy

    IL-27 is an Immunosuppressive Cytokine Upregulated During Pregnancy, an Immune-tolerant State Detection of EBI3 (IL-27 subunit) in Serum

  25. Slide 25: IL-27 Upregulates Checkpoint Receptors, Downregulates Proinflammatory Cytokines

    IL-27 Upregulates Checkpoint Receptors, Downregulates Proinflammatory Cytokines IL-27 Receptor p28 Jak2 Jak1 STAT3 STAT1 Inflammatory Cytokines EBI3 IL-27 Ligand Inhibitory Receptors on Immune Cells IL-27 Upregulates Checkpoint Receptors IL-27 Downregulates Pro-Inflammatory Cytokines TNF⍺ +IL-27 Con

  26. Slide 26: SRF388 Restores Cytokine Production in Combination with αPD-1

    IL-27 SRF388 Restores Cytokine Production in Combination with αPD-1 in Presence of rIL-27 in Healthy Donor PBMCs IFNγ, TNFα, IL-17 T cell PD1 Control ⍺PD-1 IL-27 + ⍺PD-1 IL-27 + ⍺PD-1 + SRF388 Anti-PD-1 SRF388 Similar effects observed with IL-17 and TNFa Anti-PD-1

  27. Slide 27: Levels of EBI3 are Elevated in Serum from Cancer Patients

    Levels of EBI3 are Elevated in Serum from Cancer Patients

  28. Slide 28: Evidence for IL-27 Pathway Activation in HCC and RCC

    Evidence for IL-27 Pathway Activation in HCC and RCC P28 Expression in Hepatocellular Carcinoma U. Montreal Cohort - J. Stagg 187 RCC Plasma Samples Liver

  29. Slide 29: SRF388 Inhibits Tumor Growth in an Orthotopic Model of HCC

    SRF388 Inhibits Tumor Growth in an Orthotopic Model of Hepatocellular Carcinoma SRF388 (50 mg/kg) was dosed IP BIW x 2 Starting day 5 Tumor growth was measured by bioluminescent imaging Hepa1-6-Luc Tumors

  30. Slide 30: SRF388 Clinical Development Plan Phase 1/1b

    Potential to explore combinations in RCC Single arm Phase 2 in RCC Renal Cell Cancer Monotherapy dose expansion (Mandatory pre & post-treatment biopsies) Hepatocellular Cancer Monotherapy safety Potential to explore combinations in HCC Monotherapy dose escalation in patients with advanced solid tumo

  31. Slide 31: Overview of SRF388: Potential First-in-Class Antibody Targeting IL-27

    Overview of SRF388 Potential First-in-Class Antibody Targeting IL-27 High affinity, fully human IgG1 antibody against the p28 subunit of IL-27 IL-27 is a highly immunosuppressive cytokine upregulated during pregnancy and associated with maternal-fetal tolerance Targeted translational hypothesis: RCC

  32. Slide 32: Overview of SRF813 Targeting CD112R to Enhance NK & T cell Activity

    Overview of SRF813 Targeting CD112R to Enhance NK & T cell Activity in the TME

  33. Slide 33: NK Focused Immunotherapies Provide a Strategy to Overcome Tumor Immune Resistance

    NK Focused Immunotherapies Provide a Strategy to Overcome T Cell-Associated Tumor Immune Resistance Freeman, et al Cell Reports, 28, 2019 Genes that when depleted are associated with increased sensitivity to NK mediated killing Tumor cell NK cell MHC I low NK sensitivity Genes that when depleted pro

  34. Slide 34: The CD112R Blocking Antibody SRF813 Promotes NK Cell Activation

    The CD112R Blocking Antibody SRF813 Promotes NK Cell Activation NK cell Tumor cell CD112 PBMC-NK activation assay NK degranulation assay Raji.CD112 Cells K562 Cells SRF813 + + activation + + + CD16 CD112R CD226

  35. Slide 35: SRF813 Has the Potential for Improved Efficacy

    SRF813 Has the Potential for Improved Efficacy In vitro NK cell activity assay K562 Cells CD16 CD112R Distinct epitope and isotype important for functional activity Competitor Model for SRF813 binding CD112 SRF813 + Tumor cell NK Cell CD226 + - CT26 syngeneic tumor model muIgG1 = low affinity bindin

  36. Slide 36: CD112R Antibody Delays Tumor Growth and Promotes Immunological Memory

    CD112R Antibody Delays Tumor Growth and Promotes Immunological Memory Anti-muCD112R 25 mg/kg, starting day 4 (BIW x 3) Anti-tumor activity as a single agent Naive Re-challenged Tumor free re-challenged display immunological memory Activity is NK and T cell dependent Isotype anti-muCD112R

  37. Slide 37: SRF813 Antibody Targeting CD112R

    High affinity, fully human IgG1 antibody against human CD112R NK cell targeted therapies have the potential to overcome PD-1 resistance SRF813 represents a new therapeutic approach designed to enhance NK/T cell activation in the TME SRF813 enhances NK cell and T cell activation via a distinct mechan

  38. Slide 38: Upcoming Milestones

    IND-enabling work ongoing PROGRAM CANDIDATE KEY NEAR TERM MILESTONES Initial Phase 1 results Combinations with anti-PD-1 and A2AR Initiate Phase 1 in early 2020 Initial clinical update in late 2020 Initiate Phase 1 in early 2020 Initial clinical update in late 2020 Upcoming Milestones Next Wave of P

  39. Slide 39: Breaking through for patients with cancer

    Breaking through for patients with cancer

Surface Oncology — Investor Presentation (January 2020) on 6ix